By: Kazunori Miura
Pharmaceutical access is measured at the bedside, not at the time of approval. A medicine may have a clear review yet still be out of reach because coverage, cost, site readiness, or documentation stalls treatment. These barriers affect patients, caregivers, clinicians, payors, and manufacturers across our health system. Strong access planning brings clinical evidence, payment logic, and care…